Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 272,555,072
  • Shares Outstanding, K 2,535,396
  • Annual Sales, $ 48,704 M
  • Annual Income, $ 13,049 M
  • 60-Month Beta 0.38
  • Price/Sales 5.56
  • Price/Cash Flow 14.60
  • Price/Book 6.08
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 21.30% ( -0.26%)
  • Historical Volatility 21.35%
  • IV Percentile 9%
  • IV Rank 12.86%
  • IV High 33.74% on 11/30/21
  • IV Low 19.47% on 03/25/22
  • Put/Call Vol Ratio 0.64
  • Today's Volume 17,644
  • Volume Avg (30-Day) 42,458
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 610,575

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 1.54
  • Number of Estimates 6
  • High Estimate 1.73
  • Low Estimate 1.49
  • Prior Year 1.80
  • Growth Rate Est. (year over year) -14.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.33 +10.45%
on 11/11/22
107.50 unch
on 11/25/22
+9.79 (+10.02%)
since 10/25/22
3-Month
84.52 +27.19%
on 09/21/22
107.50 unch
on 11/25/22
+17.23 (+19.09%)
since 08/25/22
52-Week
71.50 +50.35%
on 12/07/21
107.50 unch
on 11/25/22
+25.22 (+30.65%)
since 11/24/21

Most Recent Stories

More News
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

AZN : 66.17 (+0.08%)
MRK : 107.50 (+0.64%)
ANGN : 0.9000 (+5.88%)
CLVS : 0.3460 (+1.76%)
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication

Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.

GSK : 33.99 (+0.89%)
MRK : 107.50 (+0.64%)
ABBV : 159.62 (+0.14%)
IMGO : 35.66 (+0.06%)
4 Stocks to Buy That Have Caught Wall Street's Attention

With strong indications of slowing interest rate hikes by the Fed poised to feed the stock market rally, it could be wise to invest in Merck (MRK), AT&T (T), Mosaic (MOS), and Photronics (PLAB), which...

MOS : 51.77 (+2.31%)
MRK : 107.50 (+0.64%)
PLAB : 18.69 (-1.58%)
T : 19.12 (+0.16%)
2 Stocks the Smart Money on Wall Street Owns the Majority Right Now

The Federal Reserve is expected to lower the pace of its rate hikes from next month. However, concerns about an economic slowdown are still evident. Hence, this might be the time to follow the smart money...

MRK : 107.50 (+0.64%)
YELP : 29.64 (+0.24%)
Novartis (NVS) Set to Advance Malaria Drug Into Phase III

Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.

NVS : 87.71 (+0.48%)
BIIB : 305.15 (+0.56%)
RHHBY : 41.0600 (+1.08%)
MRK : 107.50 (+0.64%)
Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations

Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decision...

BMY : 79.24 (+0.13%)
MRK : 107.50 (+0.64%)
AMGN : 283.74 (+0.12%)
MRTX : 98.62 (+2.89%)
AbbVie's (ABBV) Skyrizi Gets EU Nod for Crohn's Disease

AbbVie's (ABBV) Skyrizi becomes the first specific IL-23 inhibitor to get approval for Crohn's disease in the European Union.

MRK : 107.50 (+0.64%)
GILD : 86.26 (+0.98%)
VRTX : 312.98 (-1.01%)
ABBV : 159.62 (+0.14%)
Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.

BMY : 79.24 (+0.13%)
MRK : 107.50 (+0.64%)
VRTX : 312.98 (-1.01%)
ANGN : 0.9000 (+5.88%)
GSK to Withdraw Blenrep From U.S. Market on FDA Request

GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.

GSK : 33.99 (+0.89%)
MRK : 107.50 (+0.64%)
GILD : 86.26 (+0.98%)
VRTX : 312.98 (-1.01%)
The Zacks Analyst Blog Highlights Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co

Archer-Daniels-Midland, McKesson, Marathon Petroleum, Exxon Mobil and Merck & Co are part of the Zacks top Analyst Blog.

XOM : 113.21 (-0.35%)
MRK : 107.50 (+0.64%)
ADM : 97.40 (+0.64%)
MCK : 383.34 (+0.68%)
MPC : 125.20 (-0.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 108.75
2nd Resistance Point 108.13
1st Resistance Point 107.81
Last Price 107.50
1st Support Level 106.87
2nd Support Level 106.25
3rd Support Level 105.93

See More

52-Week High 107.50
Last Price 107.50
Fibonacci 61.8% 93.75
Fibonacci 50% 89.50
Fibonacci 38.2% 85.25
52-Week Low 71.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar